Home › Lung Cancer › NCT06688422
Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
Incentive Spirometry for Respiratory Enhancement Pilot Clinical Trial in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Confirmed diagnosis of advanced non-small-cell lung cancer * Performance status (ECOG 0-1) * Eligible for concurrent chemotherapy and radiation * 18 years or older Exclusion Criteria: * Previous lung or thoracic surgery * Enrollment in another pulmonary intervention trial * Home oxygen usage prior to enrolment * Radiological evidence of pleural effusion, pneumothorax, bullous emphysema, - or pneumonitis on staging imaging * Presence of active respiratory tract infection * Uncontrolled nausea and vomiting * Prior exposure to drugs such as amiodarone, bleomycin, or immunotherapy * Inability or unwillingness of individual to give written informed consent
About the study
The goal of this clinical trial is to learn if using an incentive spirometer can reduce lung problems in people with advanced lung cancer who are receiving chemotherapy and radiation therapy. The main questions the study aims to answer are:
Does using an incentive spirometer lower the chances of developing lung inflammation (pneumonitis)? Does it improve overall survival and quality of life?
Participants will:
Use an incentive spirometer, a device that helps with deep breathing, 10 times every hour while awake.
Continue using the spirometer daily during treatment and for up to three months after treatment.
Complete quality of life assessments at the start of the study and at 3, 6, and 12 months.
Researchers will compare the results to see if the incentive spirometer helps reduce lung problems and improves participants\' well-being during and after their cancer treatment.
What is being tested
- incentive spirometry (device)
Sponsor: The Cooper Health System · Participants: 100 · Started: Dec 1, 2024
Contact the study team
- Veli Bakalov, MD · Phone: 856-735-6100
Official record on ClinicalTrials.gov — NCT06688422
Locations in the U.S.
| New Jersey | MD Anderson Cancer Center at Cooper, Camden |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.